
Opinion|Videos|December 5, 2024
Balancing Safety and Efficacy With Key Data
Author(s)James Song, MD, FAAD
Key Takeaways
James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The Aesthetic Edge: January 2026
3
Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa
4
LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD
5




















